In-vitro and in-vivo study of amorphous spironolactone prepared by adsorption method using supercritical CO2

Drug Development and Industrial Pharmacy

Volumn 41, Issue 2, 2015, Pages 201-206

  Jiang, Qikun ^a   Li, Yuanyuan ^a   Fu, Qiang ^a   Geng, Yajie ^a   Zhao, Juanhang ^a   Ma, Panqin ^b   Zhang, Tianhong ^a  

^a SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

^b Kangya of Ningxia Pharmaceuticals COLTD   (China)

Author keywords

Amorphous; Fumed silica; Oral bioavailability; Spironolactone; Supercritical carbon dioxide

Indexed keywords

ACETIC ACID; BUFFER; CARBON DIOXIDE; SILICON DIOXIDE; SPIRONOLACTONE; WATER; DIURETIC AGENT;

ADSORPTION; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; DIFFERENTIAL SCANNING CALORIMETRY; DISSOLUTION; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG SOLUBILITY; DRUG STRUCTURE; EXPERIMENTAL DOG; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PH; SCANNING ELECTRON MICROSCOPY; TABLET; X RAY DIFFRACTION; ANIMAL; BIOAVAILABILITY; CHEMISTRY; CROSSOVER PROCEDURE; DOG; MEDICINAL CHEMISTRY; ORAL DRUG ADMINISTRATION; POWDER DIFFRACTION; SOLUBILITY; SUPERCRITICAL FLUID CHROMATOGRAPHY;

ADMINISTRATION, ORAL; ADSORPTION; ANIMALS; BIOLOGICAL AVAILABILITY; CALORIMETRY, DIFFERENTIAL SCANNING; CARBON DIOXIDE; CHEMISTRY, PHARMACEUTICAL; CHROMATOGRAPHY, SUPERCRITICAL FLUID; CROSS-OVER STUDIES; DIURETICS; DOGS; IN VITRO TECHNIQUES; MICROSCOPY, ELECTRON, SCANNING; POWDER DIFFRACTION; SILICON DIOXIDE; SOLUBILITY; SPIRONOLACTONE;

EID: 84921913230     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.3109/03639045.2013.858731     Document Type: Article

References (20)

1. Atkinson SA, Shah JK, McGee C, Steele BT. Mineral excretion in premature infants receiving various diuretic therapies. J Pediatr 1988;113:540-5.
2. Clarke JM, Ramsay LE, Shelton JR, et al. Factors influencing comparative bioavailability of spironolactone tablets. J Pharm Sci 1977;66:1429-32.
3. Mclnnes GT, Asbury MJ, Ramsay LE, et al. Effect of micronization on the bioavailability and pharmacologic activity of spironolactone. J Clin Pharmacol 1982;22:410-17.
4. Dong Y, Ng WK, Shen S, et al. Preparation and characterization of spironolactone nanoparticles by antisolvent precipitation. Int J Pharm 2009;375:84-8.
5. Limayem Blouza I, Charcosset C, Sfar S, Fessi H. Preparation and characterization of spironolactone-loaded nanocapsules for paediatric use. Int J Pharm 2006;325:124-31.
6. Laouini A, Jaafar-Maalej C, Sfar S, et al. Liposome preparation using a hollow fiber membrane contactor - application to spironolactone encapsulation. Int J Pharm 2011;415:53-61.
7. Abd Elazeem Soliman O, Kimura K, Hirayama F, et al. Amorphous spironolactone-hydroxypropylated cyclodextrin complexes with superior dissolution and oral bioavailability. Int J Pharm 1997;149: 73-83.
8. Fages J, Lochard H, Letourneau J-J, et al. Particle generation for pharmaceutical applications using supercritical fluid technology. Powder Technol 2004;141:219-26.
9. Türk M, Bolten D. Formation of submicron poorly water-soluble drugs by rapid expansion of supercritical solution (RESS): results for Naproxen. J Supercritical Fluids 2010;55:778-85.
10. Liu H, Zhou L, Pan W. Preparation of budesonide-poly (ethylene oxide) solid dispersions using supercritical fluid technology. Drug Dev Ind Pharm 2007;33:959-66.
11. José Cocero M, Martín A, Mattea F, Varona S. Encapsulation and co-precipitation processes with supercritical fluids: fundamentals and applications. J Supercritical Fluids 2009;47:546-55.
12. Yoda S, Otake K, Takebayashi Y, et al. Effect of supercritical fluids conditions on the properties of silica-titania aerogels. J Non-Crystalline Solids 2001;285:8-12.
13. Kinoshita M, Baba K, Nagayasu A, et al. Improvement of solubility and oral bioavailability of a poorly water-soluble drug, TAS-301, by its melt-adsorption on a pourous calcium silicate. J Pharm Sci 2002;91:362-70.
14. Chino T, Yasuno N, Yanagihara Y, Suzuki H. Solid dispersion of spironolactone with porous silica prepared by the solvent method. Pharmazie 2007;62:599-603.
15. Sathigari SK, Ober CA, Sanganwar GP, et al. Single-step preparation and deagglomeration of itraconazole microflakes by supercritical antisolvent method for dissolution enhancement. J Pharm Sci 2011;100:2952-65.
16. Sanganwar GP, Sathigari S, Jayachandra Babu R, Gupta RB. Simultaneous production and co-mixing of microparticles of nevirapine with excipients by supercritical antisolvent method for dissolution enhancement. Eur J Pharm Sci 2010;39:164-74.
17. Miura H, Kanebako M, Shirai H, et al. Enhancement of dissolution rate and oral absorption of a poorly water-soluble drug, K-832, by adsorption onto porous silica using supercritical carbon dioxide. Eur J Pharm Biopharm 2010;76:215-21.
18. Jeunesse E, Woehrle F, Schneider M, Lefebvre HP. Effect of spironolactone on diuresis and urine sodium and potassium excretion in healthy dogs. J Vet Cardiol 2007;9:63-8.
19. Jankowski A, Skorek-Jankowska A, Lamparczyk H. Simultaneous determination of spironolactone and its metabolites in human plasma. J Pharm Biomed 1996;14:1359-65.
20. Iuliana Sora D, Udrescu Ş, Albu F, et al. Analytical issues in HPLC/MS/MS simultaneous assay of furosemide, spironolactone and canrenone in human plasma samples. J Pharm Biomed 2010;52:734-40.